Breaking AI & Tech News Analyzed

A phase‑3 trial of retatrutide, a once‑weekly triple‑hormone injection, showed patients with type 2 diabetes cut HbA1c by up to 1.9 percentage points and shed up to 15 % of body weight after 40 weeks.Triple‑Hormone Mechanism Sets Retatrutide ApartThe drug combines analogues of GLP‑1, GIP and glucagon, targeting appetite, glucose regulation and energy expenditure simultaneously. Unlike Ozempic or Wegovy (GLP‑1 only) and Mounjaro (GLP‑1 + GIP), the added glucagon activity aims to boost metabolic rate.Trial Numbers Reveal Double‑Digit HbA1c Cuts and 15% Weight Loss930 adults with type 2 diabetes, BMI ≥ 23, not on other diabetes meds.Randomised to 4 mg, 9 mg or 12 mg retatrutide or placebo for 40 weeks.HbA1c reduction: 1.7‑1.9 pp vs 0.8 pp placebo.Weight loss: 11.5‑15.3 % vs 2.6 % placebo.Improvements in cholesterol and blood pressure observed.Serious adverse events in 14 participants (including 2 on placebo); most side effects were mild gastrointestinal issues.Potential Shift in Diabetes‑Obesity Treatment LandscapeExperts say the dual impact on glycaemic control and weight could reshape management pathways. Dr Kath McCullough (Royal College of Physicians) called the results “life‑changing,” while Dr Marie Spreckley (University of Cambridge) cautioned that head‑to‑head data against existing agents are still needed.For health systems such as the NHS, a drug delivering both outcomes may reduce long‑term cardiovascular complications and associated costs, but pricing and safety profiles will drive adoption.Next Steps: Head‑to‑Head Comparisons and Long‑Term SafetyFurther phase‑3 studies are planned to compare retatrutide directly with semaglutide and tirzepatide. Regulators will scrutinise the balance of metabolic benefits against gastrointestinal adverse events before approval.

Trump-Directed Trades Channel Hundreds of Millions into Eli LillyFinancial disclosures show that the Trump administration’s investment portfolio included multiple purchases of Eli Lilly shares, totalling between $220 million and $750 million in the first quarter of 2026. Seven separate acquisitions of Lilly stock, each up to $680,000, were made between 6 January and the end of March, aligning with new government programs that favour the company’s GLP‑1 weight‑loss drugs.Policy Moves Expand Access to GLP‑1 Obesity TreatmentsThe timing of the trades mirrors two key policy actions:CMS pilot program – The Centers for Medicare & Medicaid Services announced a pilot to broaden Medicare coverage for GLP‑1 medications, specifically Lilly’s Foundayo and Zepbound KwikPen.TrumpRx launch – In February, the White House unveiled TrumpRx, a direct‑to‑consumer drug‑sales platform that initially featured products from the first five manufacturers securing pricing deals, including Eli Lilly’s telemedicine service LillyDirect.Financial Scale of the Trades and Market ImpactTotal disclosed trades on Trump’s behalf in Q1 2026: several thousand across stocks and bonds.Estimated value range of all trades: $220 million–$750 million.Eli Lilly‑specific activity: seven purchases amounting to up to $680 k.Other high‑profile holdings disclosed: Apple, Boeing, Goldman Sachs, Meta, Microsoft, Nvidia.Implications for the Pharma‑Policy Nexus and Investor ScrutinyThe convergence of federal initiatives that directly benefit Eli Lilly’s GLP‑1 portfolio with simultaneous high‑value trades on the president’s behalf intensifies scrutiny over potential conflicts of interest. Critics argue that the disclosures highlight how policy decisions can create lucrative windows for politically‑linked investors, while the Trump Organization maintains that all investment decisions are made by independent third‑party managers.Future Outlook for Eli Lilly and Government‑Linked InvestingAnalysts anticipate heightened regulatory attention on disclosure practices and possible congressional inquiries into the timing of policy rollouts. If the GLP‑1 expansion continues, Eli Lilly could see sustained revenue growth, but any perception of preferential treatment may pressure the company’s stock and invite calls for stricter ethics rules governing presidential investment portfolios.

Scientists have made a groundbreaking discovery that could lead to the development of new obesity drugs. By studying the unique metabolic abilities of pythons, researchers have identified a molecule that appears to play a crucial role in regulating appetite and weight loss. The molecule, called pTOS, was found to increase significantly in the blood of pythons after they eat, and when administered to obese mice, it led to a significant reduction in food intake and a 9% loss of body weight over 28 days. The discovery could lead to the development of new obesity drugs that work in a different way to existing medications, such as GLP-1 medications like Wegovy. Unlike these medications, which can have side effects such as nausea and stomach pain, pTOS appears to act on the brain's appetite centers, reducing food intake without these adverse effects. The researchers, led by Dr. Jonathan Long from Stanford University and Prof. Leslie Leinwand from the University of Colorado Boulder, published their findings in the journal Nature Metabolism. They believe that pTOS, which is naturally produced by the snake's gut bacteria and also found in human urine, could be a safe and effective treatment for obesity. While further research is needed before the findings can be applied clinically, the discovery is seen as a promising step towards the development of new obesity treatments. The study's results suggest that pTOS could be a potential therapeutic target for the treatment of obesity and related metabolic disorders.